How Well Does Semaglutide Work for Weight Loss in People Without Diabetes? A Review of 6,623 Patients

Across 10 studies (9 RCTs and 1 retrospective cohort) encompassing 6,623 non-diabetic overweight or obese participants, semaglutide in various doses and forms demonstrated consistent, significant weight loss effects. The review examined changes in body weight, waist circumference, and the proportion of patients achieving at least 5% clinically meaningful weight loss. The consolidated evidence endorsed semaglutide as a highly efficient weight-reducing agent in people without diabetes.

Systematic review following PRISMA 2020 guidelines. Three databases searched (PubMed, PubMed Central, Cochrane Library) with 423 initial papers narrowed to 10 high-quality studies published in the last 5 years. Studies were filtered using inclusion/exclusion criteria and quality appraisal tools. Included studies compared semaglutide at various doses and forms to placebo or active comparators in non-diabetic overweight/obese adults.

Most early GLP-1 RA research focused on diabetes patients, where weight loss was initially considered a side benefit. This systematic review consolidates the evidence specifically for non-diabetic populations — the primary market for drugs like Wegovy. By pooling results from 6,623 participants across high-quality studies, it provides a comprehensive evidence base supporting semaglutide's use purely as a weight loss treatment.

This review captures the evidence supporting semaglutide's transition from a diabetes drug to a mainstream weight loss treatment. With Wegovy (semaglutide 2.4 mg) now prescribed to millions of non-diabetic patients, consolidating the efficacy evidence for this specific population is important for clinical practice. The review arrives as the obesity drug market is projected to reach $100+ billion and as debate continues about insurance coverage, access, and long-term use.

This is a systematic review without meta-analysis — the results are described qualitatively rather than pooled statistically. Published in Cureus (a lower-impact journal), and the abstract doesn't report specific weight loss numbers, making it difficult to assess the magnitude of effects. The review's conclusion is broad ('highly efficient') without distinguishing between dose-specific outcomes. Only studies from the last 5 years were included, potentially missing earlier relevant data.